Evidence map›Paper›PMID 38680351›Full record

ArticleACS omega2024

Structure-Guided Design, Synthesis, and Biological Evaluation of Peripheral Anionic Site Selective and Brain Permeable Novel Oxadiazole-Piperazine Conjugates against Alzheimer's Disease with Antioxidant Potential.

Abhinav Singh, Akash Verma, Bhagwati Bhardwaj, Poorvi Saraf, Hansal Kumar, Nishi Jain, Digambar Kumar Waiker, T A Gajendra, Sairam Krishnamurthy, Sushant K Shrivastava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abhinav SinghPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Akash VermaPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Bhagwati BhardwajPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Poorvi SarafPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Hansal KumarPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Nishi JainPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Digambar Kumar WaikerPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
T A GajendraNeurotherapeutics Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Sairam KrishnamurthyNeurotherapeutics Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.
Sushant K ShrivastavaPharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology, (Banaras Hindu University), Varanasi 221005, India.ORCID https://orcid.org/0000-0002-5500-4004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a multifactorial and emerging neurological disorder, which has invoked researchers to develop multitargeted ligands. Herein, hybrid conjugates of 5-phenyl-1,3,4-oxadiazole and piperazines were rationally designed, synthesized, and pharmacologically evaluated against hAChE, hBChE, and hBACE-1 enzymes for the management of AD. Among the series, compound

Identifiers

PMID38680351
PMCPMC11044217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.